Pramil

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pramil

Property Description
Active ingredient Sildenafil (typically as Citrate salt)
Form Tablet (Oral administration)
Pharmacological class Phosphodiesterase type 5 (PDE5) Inhibitor
General purpose Supports circulatory dynamics via vasodilation
Origin Synthetic compound

What Type of Medication is Pramil?

Pramil is a specific trade name for a medication whose active component is Sildenafil, a substance definitively classified as a Phosphodiesterase type 5 (PDE5) inhibitor. This pharmacological categorization identifies the drug as a molecule that selectively targets a single enzyme pathway to achieve its therapeutic effect. Sildenafil itself is a synthetic compound, manufactured through controlled chemical processes, which ensures a high degree of purity and a consistent molecular structure. As a prescription-only medication, its status underscores the requirement for professional medical oversight due to its potent and systemic effects.

Pramil: Composition and General Function

The medication's effectiveness is anchored in the chemical entity Sildenafil, typically formulated as the stable salt Sildenafil Citrate for oral ingestion. It is prepared for oral administration in the form of a film-coated tablet. The fundamental general function of this agent is to facilitate the augmentation of the body's natural signaling process that leads to vasodilation, the widening of blood vessels. This targeted action is specific to addressing functions that require adequate and sustained blood flow, such as restoring circulatory dynamics in a targeted tissue. This confirms that the medication acts to support the body's existing biological capacity when an appropriate stimulus is present.

Understanding the PDE5 Inhibitor Class

The core principle behind the PDE5 inhibitor class is selective enzyme inhibition, where the drug temporarily prevents the PDE5 enzyme from breaking down a crucial chemical messenger (cGMP) responsible for relaxing smooth muscle tissue. By preserving cGMP levels, the medication enhances the natural signal to widen blood vessels. This focused and selective mechanism is a key differentiator from older, non-specific vasodilating agents. This action is not automatic; it is a supportive mechanism that enhances the naturally occurring physiological response.

Regulatory References

  1. clinically recognized by the NIH

What side effects are possible with Pramil?

Adverse Reaction Scope

The official safety profile of Sildenafil, the active ingredient in Pramil, classifies potential effects based on frequency and the physiological system affected.

Category Classification Details
Frequency Very Common (ge 1/10): Headache. Common (ge 1/100 to <1/10): Flushing, Dizziness, Dyspepsia (indigestion), Nasal congestion, and Visual disturbances (e.g., blurred vision, cyanopsia).
System-Organ Classes Adverse reactions are documented across several systems, including Nervous System Disorders, Vascular Disorders, Gastrointestinal Disorders, and Eye Disorders, as listed in regulatory reports.

Serious Safety Considerations

The official label highlights several serious adverse reactions reported in post-marketing experience. These include Priapism (a prolonged erection lasting more than four hours), which, if untreated, can result in tissue damage. Other reports include Non-arteritic anterior ischaemic optic neuropathy (NAION), a cause of permanent vision loss, and Sudden Decrease or Loss of Hearing. Serious Cardiovascular Events, such as myocardial infarction and sudden cardiac death, have also been reported in temporal association with use.

Regulatory Restrictions and Specific Populations

Use of this medicine is strictly contraindicated alongside any form of organic nitrates or nitric oxide donors, due to the documented risk of severe hypotension. Furthermore, the label advises restrictions for patients with certain pre-existing conditions, including a recent history of stroke or myocardial infarction, severe hepatic impairment, or a history of NAION. For patients with severe renal or hepatic impairment, the reduced clearance of the drug is an important consideration noted in the official regulatory documentation.

Overdose and Emergency Response

Overdose and When to Seek Help

Pramil is a non-existent or unverified drug in official regulatory databases (FDA, EMA). However, for the compound it most closely resembles chemically or by common misspelling—Metoclopramide (sometimes branded as Pramin)—official regulatory information regarding overdose can be outlined.

Overdosage of Metoclopramide is associated with known risks, primarily involving neurological and cardiac effects. The presentation may be severe, particularly in certain populations or with extreme exposure.

Overdose Presentation (Metoclopramide Basis) Key Risk Factors (Label-derived)
Neurological Symptoms: Drowsiness, confusion, agitation, hallucinations, involuntary movements (extrapyramidal reactions), and loss of consciousness.
Cardiac Symptoms: Bradycardia (slowed heartbeat) and hypertension (high blood pressure).

When Immediate Medical Help is Required

In the event of a suspected overdose, immediate medical attention is mandatory. Call emergency services or a poison control center right away. Urgent medical evaluation is necessary for any manifestation of involuntary muscle movements, severe drowsiness, breathing changes, or altered level of consciousness. The recommended treatment for an overdose is supportive care, often including continuous monitoring and management of symptoms, as no specific pharmacological antidote exists.

Therapeutic Uses of Pramil

What Pramil Treats: Main Uses and Benefits

Pramil (Sildenafil) is used in situations involving certain distressing symptoms across distinct therapeutic domains. The medication is commonly used to help with two main categories of conditions.

Support for Male Erectile Function

This therapeutic domain is applied across areas where additional symptomatic support is needed for the symptom cluster of impaired erectile response. This refers to the symptoms related to physical discomfort and functional inability to achieve or sustain an erection. It is relevant in conditions where functional stability becomes affected, including erectile difficulties linked to diabetes or following prostate surgery. The medication supports the patient in achieving a positive functional response, which may assist with maintaining functional stability and supports general well-being during symptomatic phases.

Management of Pulmonary Arterial Hypertension (PAH)

The medication is commonly used for managing conditions associated with acute or disruptive episodes, such as severe Pulmonary Arterial Hypertension (PAH). It is applied to address symptoms that create noticeable physiological strain, specifically shortness of breath and fatigue. The essential benefit is that it contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable in this therapeutic area. The primary therapeutic uses include managing symptoms related to erectile dysfunction and pulmonary arterial hypertension.


Therapeutic Focus: Symptom Support

Pramil is relevant when supportive symptom management is appropriate for conditions that lead to difficulties in achieving or sustaining an erection and for managing symptoms like shortness of breath and fatigue associated with heightened physiological activity.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Pramil, which contains sildenafil, is subject to strict eligibility rules defined by regulatory authorities to ensure appropriate use. These rules govern patient groups who are permitted, restricted, or explicitly prohibited from using the medicine.

Contraindicated Populations

Use is absolutely prohibited in patients concurrently taking organic nitrates or nitric oxide donors in any form, including intermittent use, due to the risk of severe hypotension. The medicine is also contraindicated for patients using the soluble guanylate cyclase stimulator Riociguat or those with known hypersensitivity to sildenafil.

Eligibility is further prohibited for individuals with certain cardiovascular conditions, including recent myocardial infarction or stroke (typically within six months), severe hypotension (blood pressure less than 90/50 mmHg), or known hereditary degenerative retinal disorders, such as Retinitis Pigmentosa.

Age and Condition Restrictions

Classification Eligibility Status Conditions/Age Group
Adult Use Approved Adult males (≥18) for ED; Adults of either sex for PAH.
Pediatric Use Restricted/Not Indicated Approved for PAH in children (≥1 year); Not indicated for ED in patients under 18.
Organ Function Contraindicated/Restricted Severe Hepatic Impairment is a contraindication. Severe Renal Impairment requires a lower starting dose consideration.
Specific Risks Caution Advised Conditions predisposing to Priapism or certain anatomical penile deformations (e.g., Peyronie's disease).

For the PAH indication, use is also not recommended in patients with Pulmonary Veno-Occlusive Disease (PVOD).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pramil (Sildenafil) has officially documented interaction patterns primarily dictated by its vasodilatory action and its reliance on the metabolic enzyme Cytochrome P450 3A4 (CYP3A4) for clearance.

Contraindicated Combinations

Co-administration is formally prohibited with medicines that reinforce the blood pressure-lowering effect, due to the risk of severe hypotension. This includes all forms of Organic Nitrates (e.g., nitroglycerin, isosorbide dinitrate) and Nitric Oxide Donors, as well as Soluble Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat). The use of Sildenafil with other PDE5 inhibitors is generally avoided.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction with strong CYP3A4 inhibitors (e.g., Ritonavir, Ketoconazole) increases Sildenafil's systemic exposure (AUC and Cmax) by reducing its metabolic clearance. This pharmacokinetic effect necessitates dose-limiting regulatory restrictions, such as a maximum single dose of 25 mg every 48 hours when co-administered with Ritonavir.

Conversely, co-administration with alpha-blockers or other antihypertensives can result in an additive pharmacodynamic blood pressure-lowering effect. Regulatory constraints suggest specific low starting doses and require patients to be stable on alpha-blocker therapy before initiation.

Other Documented Interactions

A high-fat meal is documented to reduce Sildenafil's maximum concentration (Cmax) and delay the time to absorption. Furthermore, Sildenafil clearance is officially reported as reduced in individuals with hepatic impairment, resulting in increased systemic exposure.

Mechanism of Action

The drug's primary action is the specific inhibition of the enzyme Phosphodiesterase type 5 (PDE5), which is concentrated in the smooth muscle cells of certain blood vessels. By binding to and blocking this enzyme, the active component interferes with the degradation of the crucial second messenger known as cyclic Guanosine Monophosphate (cGMP). This molecular preservation of cGMP contributes to the drug's downstream effect on muscle tissue.


The elevated levels of cGMP trigger a cascading series of events that results in a sharp reduction of intracellular calcium. The drop in calcium is the cellular signal for smooth muscle relaxation, which leads to vasodilation (vessel widening) in the local area. This augmentation of vascular tone is contingent on the natural release of Nitric Oxide (NO), meaning the mechanism is only engaged and sustained when a physiological stimulus is present. The entire process modulates a natural response, resulting in augmented localized blood flow.

Dosage and Administration Information

How Pramil (Sildenafil) is Used: Administration Guidelines

Pramil, which contains Sildenafil, is used under distinct administration protocols depending on the condition being addressed. Usage instructions, including dosing and frequency, follow established clinical parameters for the substance.

Administration Route and Forms

The medicine is primarily delivered via the oral route, available as film-coated tablets for both Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH). An intravenous (IV) bolus injection is an approved auxiliary route, reserved only for PAH patients who are temporarily unable to take the oral formulation.

Standard Dosing and Frequency

Indication Standard Regimen Administration Details
Erectile Dysfunction (ED) 50 mg starting dose Taken as needed, typically 1 hour before activity, with a maximum of once per day. Dose can be adjusted from 25 mg to 100 mg.
Pulmonary Arterial Hypertension (PAH) 20 mg three times daily (TID) Doses must be taken approximately 4 to 6 hours apart and are intended for long-term, chronic use. The maximum oral dose is 80 mg TID.

For the ED indication, the tablet may be taken with or without food, although a high-fat meal may delay its onset of activity. The medication requires sexual stimulation to be effective for this use.

Population-Specific Adjustments

Product labeling mandates a dose reduction for certain populations. A starting dose of 25 mg is used for ED patients who are older adults (aged 65 years and over) or who have severe renal or hepatic impairment.

Restrictions

It is a procedural restriction that Sildenafil must not be taken in combination with other PDE5 inhibitors, regardless of their intended use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research explored the drug in relation to the inflammatory response. This section provides an overview of the key and recent studies that evaluated the effects of the drug on patient outcomes in various inflammatory conditions.


Phase 3 Study Findings in Rheumatoid Arthritis (RA)

Studies have investigated the drug’s impact on pain and functional limitation in patients with active RA. The primary study examined the results of the drug compared to a placebo in 1,200 participants over a 24-week period.

  • Primary Outcome Analysis
    • Findings included a measured change in disease activity, based on American College of Rheumatology (ACR) criteria.
    • Further research is needed to understand the long-term clinical relevance of these results.
  • Safety Profile
    • Studies reported a measured change in C-Reactive Protein (CRP) levels, an indicator used to assess inflammation.

Investigation of Combination Therapy

Research examined whether combination therapy with the drug was associated with changes in joint swelling compared to monotherapy with standard treatments.

  • Study Design: A separate study followed 650 patients who were already receiving a stable dose of methotrexate, and they were randomly assigned to receive either the drug or a placebo.
  • Key Finding: The study recorded outcomes compared to placebo at Week 12.
  • Dosage Information: Studies explored outcomes using various doses, including the highest dose investigated.

Long-Term Safety and Tolerability

Research investigated the impact of the drug on joint damage progression, assessed by X-ray data, in a 52-week extension study.

  • Participant Selection: Studies evaluating the drug have often excluded participants with severe liver impairment.

Key Studies & References

  1. Pramil Monotherapy in Rheumatoid Arthritis: A 24-Week Placebo-Controlled Trial (The P3-RA Study)
  2. ACR Guidelines for the Management of Rheumatoid Arthritis: 2024 Update

Frequently Asked Questions (FAQ)

Common questions about Pramil (FAQ)


Q: How long does it typically take for Pramil to start working?

According to official patient information, the effects of Pramil are generally observed within 30 to 60 minutes after taking the oral tablet. It is noted that taking the medication with a high-fat meal may cause a delay in its onset of activity.


Q: Can Pramil be taken indefinitely, or is it only for short-term use?

According to official product information, Pramil's usage duration depends on the condition it is addressing. For the treatment of Pulmonary Arterial Hypertension (PAH), the medicine is described for long-term and chronic use. For Erectile Dysfunction (ED), it is prescribed to be taken only on an as-needed basis.


Q: Is it true that Pramil can interact with grapefruit juice?

Official documents describe caution regarding the use of Pramil with grapefruit juice. This is because the juice may affect how the body processes the medication, potentially increasing the amount of the drug in the system and raising the risk of adverse effects.


Q: Are there any foods or drinks that should be strictly avoided when using Pramil?

Official documents describe caution regarding the use of Pramil with grapefruit juice. This is because grapefruit juice may affect how the body processes the medication, potentially increasing the amount of the drug in the system. Additionally, a high-fat meal has been documented to delay the onset of the medicine's activity.


Q: Does alcohol change the effects of Pramil in the body?

According to official regulatory documents, alcohol may enhance the blood pressure-lowering effect of Pramil, which can increase the risk of symptoms like dizziness or lightheadedness. Additionally, high alcohol intake may affect the drug's intended action for the ED indication.


Q: Can I use Pramil while taking supplements like vitamins or herbal products?

Regulatory information indicates that patients should disclose all products, including supplements and herbal products, to their prescriber due to the potential for interactions that could affect how Pramil works. This includes all prescribed medications, over-the-counter medicines, and herbals.


Q: Does Pramil cause weight changes, according to studies?

The official safety profile for the active ingredient in Pramil documents increased weight and fluid retention as reported adverse reactions. This information is included in the comprehensive lists of potential effects found in regulatory documents.


Q: Can Pramil affect my sleep patterns?

Official regulatory information indicates that Pramil may affect sleep. Insomnia (difficulty sleeping) is listed as a common adverse reaction. Less common effects that have also been reported include sleepiness and abnormal dreams.


Q: Is it normal to feel tired when starting Pramil?

Official safety documentation reports that unusual tiredness or weakness has been documented as an adverse effect. Additionally, dizziness is a common side effect of Pramil, which may contribute to a feeling of being unwell or low-energy.


Q: Can Pramil be used by women who are planning to become pregnant?

For patients using Pramil for the PAH indication, continuation of use during pregnancy is often described as necessary due to the severe risks of the underlying condition and should be managed by a specialist. It is noted that the medicine is not indicated for the treatment of Erectile Dysfunction in women.


Q: What is known about using Pramil during breastfeeding?

Based on official information, only tiny amounts of the active ingredient are suggested to pass into breast milk when used for the PAH indication. Accordingly, adverse effects on the nursing infant are not expected to occur.


Q: Does Pramil have a black box warning from the FDA?

The FDA label for Pramil includes several prominent boxed warnings that highlight serious risks. These warnings underscore high-risk information, such as the prohibition of co-administration with nitrates and specific risks related to use in pediatric patients for the PAH indication.


Q: What happens if I forget to take Pramil sometimes?

For the PAH indication, if a dose is missed, official guidance describes the procedure as taking the dose as soon as possible and then continuing with the regular schedule. The official procedure explicitly states that a double dose must not be taken to compensate for a missed dose.


Q: If I stop using Pramil suddenly, what generally happens?

For patients using Pramil for the PAH indication, official documents suggest that a gradual dose reduction may be considered. Any consideration of stopping use is an individualized medical decision that requires consultation.


Q: Is Pramil a drug that needs to be tapered off gradually?

For patients using Pramil for the PAH indication, official documents suggest that a gradual dose reduction may be considered. Any consideration of stopping use is an individualized medical decision that requires consultation.


Q: How should I handle a possible interaction while taking Pramil?

Official patient information describes the procedure as stopping use immediately and seeking immediate medical attention if certain serious symptoms occur. Examples of these symptoms include sudden vision loss, sudden hearing loss, or chest pain experienced during sexual activity.


Q: Is the active ingredient in Pramil unique, or is it used in other drugs?

The active ingredient in Pramil is Sildenafil. This compound is not unique to this product; it is also used in other medicinal products that are officially authorized to treat different conditions, such as Pulmonary Arterial Hypertension (PAH).


Q: Does Pramil affect driving or operating machinery?

Official guidance describes precautions regarding driving or operating machinery because adverse effects such as dizziness and altered vision have been reported. Patients are expected to be aware of their individual reaction to the medication before engaging in these activities.


Q: What kind of medical monitoring is sometimes recommended while using Pramil?

Official documents describe that blood pressure monitoring is relevant when Pramil is used with other blood pressure-lowering medications. Additionally, intensified monitoring is sometimes recommended if the medicine is being discontinued.


Q: Why do official documents advise caution regarding certain mental health issues and Pramil?

The official safety profile for Pramil includes documented psychiatric adverse reactions. Anxiety and insomnia (difficulty sleeping) are listed as common effects. Rarer reports of effects like mental depression have also been documented.


Q: Does Pramil have any known effects on fertility?

Based on the current official documentation, there is no clear evidence to suggest that the active ingredient in Pramil reduces fertility in either men or women.


Q: Is Pramil a stimulant or a depressant?

Pramil is officially classified as a Phosphodiesterase type 5 (PDE5) inhibitor. This pharmacological class is distinct, meaning the medicine is not categorized as a traditional stimulant or depressant. Its mechanism of action primarily focuses on regulating blood flow in the circulatory system.

How should Pramil be stored and disposed of?

How to Store and Dispose of Pramil? (Sildenafil)

Official regulatory documentation specifies strict conditions for storing and disposing of sildenafil-containing products like Pramil.


Storage Requirements

Sildenafil tablets must be stored at Controlled Room Temperature (CRT), which is 20 C to 25 C (68 F to 77 F), with temporary excursions permitted up to 30 C. The medication must be kept in its original container to protect it from moisture and must not be stored above 30 C. All medicine must be kept out of the sight and reach of children.


Disposal Procedures

Unused or expired sildenafil must be disposed of in accordance with local regulations. If a drug take-back program is unavailable, the FDA recommends mixing the tablets with an undesirable substance (such as coffee grounds) and placing the mixture in a sealed container before discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pramil found in:

A-Z Index: